Obesity has become a growing concern around the world. The purpose of this study was to investigate the potential benefit of Bifidobacterium pseudolongum (B. pseudolongum) on obesity, gut microbiota, and its physiological mechanism. The obese mice model was established with a high-fat diet (HFD), and the treatment were used the strain B. pseudolongum. We investigated the changes in fat content, plasma metabolites and gut microbiota on obese mice and B. pseudolongum treated obese mice. We found that B. pseudolongum treatment significantly decreased the body mass (about 12 %), plasma triglycerides (about 12.4 %), gross energy intake (about 12.8 %), and visceral fat (about 26.5 %) in obese mice. Further, High-throughput pyrosequencing of the 16S rRNA demonstrated that B. pseudolongum treatment markedly recovered the gut microbiota dysbiosis in obese mice, including the diversity of microbiota and the ratio of Firmicutes to Bacteroidetes. B. pseudolongum treatment increased the abundance of the bacterial genus Butyricimonas and Bifidobacterium. Therefore, B. pseudolongum may have therapeutic potential for the treatment of diet-induced obesity (DIO). B. pseudolongum treatment could change host gut microbiota and provide benefits to host digestive processes that mitigate metabolic diseases.

中文翻译：

---

假双歧杆菌通过调节饲喂高脂食物的小鼠的肠道菌群来减少甘油三酸酯。

肥胖已成为全世界越来越关注的问题。这项研究的目的是调查假双歧杆菌（B. pseudolongum）对肥胖，肠道菌群及其生理机制的潜在益处。用高脂饮食（HFD）建立肥胖小鼠模型，并使用假长双歧杆菌进行治疗。我们调查了肥胖小鼠和经B.pseudolongum治疗的肥胖小鼠的脂肪含量，血浆代谢产物和肠道菌群的变化。我们发现，假长双歧杆菌的治疗显着降低了肥胖小鼠的体重（约12％），血浆甘油三酸酯（约12.4％），总能量摄入（约12.8％）和内脏脂肪（约26.5％）。此外，16S rRNA的高通量焦磷酸测序证明B。假长线治疗可显着恢复肥胖小鼠的肠道菌群失调，包括菌群的多样性和硬菌与拟杆菌的比例。假单胞菌的治疗增加了细菌丁酸杆菌属和双歧杆菌属的丰度。因此，假长双歧杆菌可能具有治疗饮食性肥胖症（DIO）的治疗潜力。假单胞菌的治疗可以改变宿主肠道菌群并为减轻消化系统疾病的消化过程提供好处。